GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
40.20
+1.08 (+2.76%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close39.12
Open39.88
Bid0.00 x 0
Ask0.00 x 0
Day's Range39.67 - 40.31
52 Week Range34.52 - 44.54
Volume3,967,180
Avg. Volume3,575,914
Market Cap99.005B
Beta0.70
PE Ratio (TTM)46.00
EPS (TTM)0.87
Earnings DateFeb 1, 2017 - Feb 6, 2017
Forward Dividend & Yield2.55 (6.53%)
Ex-Dividend Date2018-02-22
1y Target Est40.88
Trade prices are not sourced from all markets
  • Glaxo (GSK) Q1 Earnings Lag, Shingrix Vaccines Sales Solid
    Zacks14 hours ago

    Glaxo (GSK) Q1 Earnings Lag, Shingrix Vaccines Sales Solid

    Glaxo's (GSK) Q1 earnings fall short of estimates while revenues rise year over year. The company's vaccine segment performs strongly on the back of Shingrix sales.

  • Novo Nordisk’s Saxendra Could Witness Solid Growth in 2018
    Market Realist16 hours ago

    Novo Nordisk’s Saxendra Could Witness Solid Growth in 2018

    In 4Q17, Novo Nordisk’s (NVO) Saxendra generated revenues of 697 million Danish kroner, which reflected a ~38% YoY (year-over-year) growth in local currency.

  • Novo Nordisk’s Victoza Could See High Growth in 2018
    Market Realist19 hours ago

    Novo Nordisk’s Victoza Could See High Growth in 2018

    In 4Q17, Novo Nordisk’s (NVO) Victoza generated revenues of 6.3 billion Danish kroner, which reflected a ~25% YoY (year-over-year) growth in local currency.

  • Thomson Reuters StreetEventsyesterday

    Edited Transcript of GSK.L earnings conference call or presentation 25-Apr-18 1:00pm GMT

    Q1 2018 GlaxoSmithKline PLC Earnings Call

  • Glaxo's Shingles Vaccine 'Encouraging' But Shares Dip On Quarterly Lag
    Investor's Business Dailyyesterday

    Glaxo's Shingles Vaccine 'Encouraging' But Shares Dip On Quarterly Lag

    Shingrix sales were strong in the first quarter, GlaxoSmithKline said, though shares dipped on the company's broader revenue and profit lag.

  • Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release
    Market Realistyesterday

    Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release

    In 1Q18, analysts expect Sanofi’s (SNY) revenue to fall ~6.6% YoY (year-over-year) to 8.1 billion euros from 8.7 billion euros, and its earnings per share to fall to 1.13 euros from 1.42 euros. Sanofi’s stock price has fallen ~9.4% over the last 12 months and ~7.1% year-to-date. Analysts’ price target of $47.67 suggests the stock could return ~19.2% over the next 12 months based on its price of $39.95 on April 23.

  • Associated Press2 days ago

    Stronger pound weighs on revenues at drugmaker GSK

    LONDON (AP) — Pharmaceutical and consumer goods maker GlaxoSmithKline says first-quarter revenue dropped 2 percent as a stronger pound offset encouraging sales of a new shingles treatment.

  • Currency and pricing squeeze GSK as new shingles vaccine shines
    Reuters2 days ago

    Currency and pricing squeeze GSK as new shingles vaccine shines

    GlaxoSmithKline's new shingles vaccine Shingrix exceeded expectations in the first quarter, but the drugmaker's sales and earnings fell 2 percent, held back by a stronger pound and more pricing pressure in respiratory medicine. The vaccine, a rival to Merck & Co's older and less effective Zostavax, is a top priority for Chief Executive Emma Walmsley as she strives to improve GSK's drugs portfolio. Walmsley told reporters the Shingrix number was "very encouraging", although she noted that some of the revenue represented supplying necessary stock into the market.

  • GlaxoSmithKline plc Shares Sink on Q1 Earnings Miss
    InvestorPlace2 days ago

    GlaxoSmithKline plc Shares Sink on Q1 Earnings Miss

    GlaxoSmithKline plc (ADR) (NYSE:GSK) stock was down on Wednesday following an earnings miss for the first quarter of 2018.Source: Mike Mozart via Flickr (Modified)

  • GlaxoSmithKline: Operating Revenues Up in 1Q18 Earnings
    Market Realist2 days ago

    GlaxoSmithKline: Operating Revenues Up in 1Q18 Earnings

    GlaxoSmithKline (GSK) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues for 1Q18. The above chart compares the quarterly revenues and EPS for GlaxoSmithKline since 1Q17. GlaxoSmithKline reported revenues of 7.2 billion pounds in 1Q18, a 2% decline in revenues, compared to 7.4 billion pounds in 1Q17.

  • Associated Press2 days ago

    Glaxo: 1Q Earnings Snapshot

    The Brentford Middlesex, Britain-based company said it had profit of 31 cents per share. Earnings, adjusted for non-recurring costs and amortization costs, came to 68 cents per share. The results fell ...

  • Reuters2 days ago

    Currency and pricing squeeze GSK as new shingles vaccine shines

    GlaxoSmithKline's new shingles vaccine Shingrix exceeded expectations in the first quarter, but the drugmaker's sales and earnings fell 2 percent, held back by a stronger pound and more pricing pressure in respiratory medicine. The vaccine, a rival to Merck & Co's older and less effective Zostavax, is a top priority for Chief Executive Emma Walmsley as she strives to improve GSK's drugs portfolio. Walmsley told reporters the Shingrix number was "very encouraging", although she noted that some of the revenue represented supplying necessary stock into the market.

  • Currency and pricing squeeze GSK as new shingles vaccine shines
    Reuters2 days ago

    Currency and pricing squeeze GSK as new shingles vaccine shines

    GlaxoSmithKline's (GSK.L) new shingles vaccine Shingrix exceeded expectations in the first quarter, but the drugmaker's sales and earnings fell 2 percent, held back by a stronger pound and more pricing pressure in respiratory medicine. The vaccine, a rival to Merck & Co's (MRK.N) older and less effective Zostavax, is a top priority for Chief Executive Emma Walmsley as she strives to improve GSK's drugs portfolio. Walmsley told reporters the Shingrix number was "very encouraging", although she noted that some of the revenue represented supplying necessary stock into the market.

  • GlobeNewswire2 days ago

    Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018

    PHILADELPHIA and OXFORD, U.K., April 25, 2018-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, will announce financial results for the First Quarter 2018 and provide a general ...

  • Glaxo (GSK) Misses on both Earnings and Revenue in Q1
    Zacks2 days ago

    Glaxo (GSK) Misses on both Earnings and Revenue in Q1

    Glaxo's (GSK) Q1 earnings and revenue miss estimates. In the event of introduction of Advair generic in the U.S. market by mid-year, Glaxo expects adjusted EPS to be flat to down at CER in 2018.

  • Reuters2 days ago

    GSK rules out entering Shire takeover battle

    LONDON (Reuters) - GlaxoSmithKline's (GSK.L) chief executive said on Wednesday she had no interest in acquiring Shire (SHP.L), the London-listed rare diseases specialist that Takeda Pharmaceutical hopes ...

  • Financial Times2 days ago

    [$$] Stronger pound weighs on GlaxoSmithKline revenues

    GlaxoSmithKline delivered sales of £7.2bn in the first quarter of this year but faced pressures due to the strengthening of the pound against the dollar. Revenues were in line with market expectations ...

  • Reuters2 days ago

    Currency weighs on GlaxoSmithKline Q1 sales and earnings

    Drugmaker GlaxoSmithKline reported a 2 percent fall in both sales and earnings in the first quarter on Wednesday as a stronger pound offset a promising start for its new shingles vaccine Shingrix. GSK's ...

  • Financial Times2 days ago

    [$$] The London Report: Metro dives on capital ratio worries

    hit a six-month low after results from the lender showed a continued weakening of its capital ratios, which raised fears of a cash call by the year end. “We think management would be well advised to act ahead of its current stated plan of not raising fresh equity capital until 2019,” said Investec. led industrial stocks lower after Caterpillar said in a post-results conference call that the first quarter will probably be this year’s high water mark.

  • Ozempic Could Be Potential Driver for Novo Nordisk in 2018
    Market Realist2 days ago

    Ozempic Could Be Potential Driver for Novo Nordisk in 2018

    In December 2017, the FDA approved Novo Nordisk’s (NVO) Ozempic as an add-on to diet and exercise for the management of blood sugar levels in adult individuals with Type 2 diabetes.

  • Biktarvy Could Be a Major Driver for Gilead Sciences in 2018
    Market Realist2 days ago

    Biktarvy Could Be a Major Driver for Gilead Sciences in 2018

    Gilead Sciences (GILD) is planning to launch a novel HIV drug, Biktarvy, in the United States and Europe in 1H18. On February 7, Gilead secured FDA approval for Biktarvy, which is an unboosted integrase strand transfer inhibitor, bictegravir, combined with a dual nucleoside reverse transcriptase inhibitor backbone, Descovy, as an STR (single tablet regimen) for HIV-1 infected patients. Biktarvy, a differentiated HIV-1 regimen

  • Business Wire3 days ago

    Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients With COPD

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means Trelegy Ellipta can now be used by US physicians to treat a broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation or who have experienced an acute worsening of respiratory symptoms. The new indication is for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.

  • Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall
    Market Realist4 days ago

    Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall

    As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.

  • What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings
    Market Realist4 days ago

    What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings

    GlaxoSmithKline (GSK) is set to release its 1Q18 earnings on April 25, 2018. The below chart shows the company’s revenues and earnings per share (or EPS) since 1Q17 and analysts’ estimates for 1Q18. Analysts estimate the company will post EPS of 24.21 pence on revenues of 7.2 billion pounds in 1Q18.

  • What's in the Cards for Glaxo (GSK) This Earnings Season?
    Zacks7 days ago

    What's in the Cards for Glaxo (GSK) This Earnings Season?

    Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.